Jasper Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Jasper Therapeutics

14/05/2024 15:38

* Jasper Therapeutics Inc  JSPR.OQ  reported a quarterly
adjusted
loss of $1.03​​ per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of $-1.60.  The mean expectation of six analysts for the quarter
was for a loss of $1.22 per share. Wall Street expected
results to range from $-1.43 to $-1.10 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Jasper Therapeutics Inc's reported EPS for the quarter was
a
loss of $1.03​.
    * The company reported a quarterly loss of $13.73 million.
    * Jasper Therapeutics Inc shares had fallen by 29.3% this
quarter and gained 163.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 15.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Jasper
Therapeutics Inc is $65.00 
This summary was machine generated from LSEG data May 14 at
02:38 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -1.22          -1.03          Beat
 Dec. 31 2023      -1.61          -1.50          Beat
 Sep. 30 2023      -1.55          -1.60          Missed
 Jun. 30 2023      -1.50          -1.50          Met